Agency IQ

DECEMBER 1, 2023

What we expect EU regulators to do in December 2023 Welcome to AgencyIQ’s monthly roundup of EU chemical sector activities. Highlights of chemical regulatory activities Consultations open under the REACH and CLP regulations are coming to an end in December. Events happening next month include two ECHA meetings (i.e.,

Regulations 40

Regulations Production International Marketing 40

Agency IQ

MAY 3, 2024

What we expect European regulators to do in May 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

Agency IQ

SEPTEMBER 15, 2023

PFAS regulation in California (late 2023 edition) California consistently maintains its status as both one of the most important economies in the world as well as one of the most regulated states in the United States. In 2019, the state began to significantly ramp up its PFAS regulation and research.

Regulations 40

Regulations Packaging Production Organic Chemistry 40

Common Sense for Drug Policy Blog

DECEMBER 20, 2023

By 1972, the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) had instituted severe regulations that restricted access, said Roberts. These regulations were designed primarily to prevent methadone from being diverted to the street, he said. Washington, DC: The National Academies Press.

Treatment 52

Treatment Regulations Engineering FDA 52

Agency IQ

MARCH 1, 2024

What we expect EU regulators to do in March 2024 Welcome to AgencyIQ’s monthly roundup of EU chemical sector activities. ECHA consultations under the CLP Regulation closing in March CLP: Harmonized classification and labeling (CLH) Consultations on classification and labeling harmonization (CLH) are open for 60 days.

Regulations 40

Regulations Production Packaging Science 40

Agency IQ

APRIL 12, 2024

Landscape analysis: A look at the regulation of decentralized trials and what’s coming soon In the past few years, regulators and researchers have shown increased interest in leveraging decentralized trial methods – especially following the pandemic. At a February 2024 joint workshop with the U.S. Next, the U.S.

Regulations 40

Regulations Trials Clinical Trials Science 40

Broad Institute

JULY 26, 2022

Learn more Genotype-Tissue Expression (GTEx) A comprehensive public resource to study tissue-specific gene expression and regulation. Learn more Technical Workshops Our primers and workshops help researchers learn about new technologies and advances in genetics, computation, and more.

Compound Screening 52

Compound Screening FDA Approval Engineering RNA 52

Drug Channels

OCTOBER 23, 2023

With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite.

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

SEPTEMBER 16, 2024

The Patient Support Services Congress is designed to help educate and share innovative program design, latest customer strategies and practical solutions to overcome complex access barriers, enhance program performance and deliver best-in-class patient programs amidst evolving regulations. Register today.

Compliance 52

Compliance Regulations Pharmaceuticals Drugs 52

Agency IQ

AUGUST 2, 2024

What We Expect the FDA to do in August and September 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Biosimilars 40

Agency IQ

NOVEMBER 27, 2023

Its latest report serves as a powerful indicator for what EU chemical regulation is likely to resemble in the coming years should the agency receive sufficient scientific support to meet four regulatory challenges ECHA just can’t solve without further progress from the scientific community.

Animal Testing 40

Animal Testing Research Regulations Compliance 40

Agency IQ

JULY 22, 2024

Commission unveils details on plan for phasing out animal testing for chemicals safety At the REACH and CLP regulators’ meeting in July, the European Commission revealed specifics about its formal schedule to eliminate animal testing used for chemical safety assessment.

Animal Testing 40

Animal Testing Regulations Production Research 40

Agency IQ

JUNE 29, 2023

What We Expect the FDA to do in July 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

Agency IQ

JULY 8, 2024

What We Expect the FDA to do in July and August 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

NOVEMBER 18, 2020

The consolidated feedback from the physicians who have participated in hands-on workshops, is very positive. The information in this press release is information that NeoDynamics is obliged to make public pursuant to the EU Market Abuse Regulation. Breast cancer in UK. Breast cancer is the most common cancer among women in the UK.

Hospitals 52

Hospitals Clinical Development Treatment Regulations 52

Agency IQ

DECEMBER 11, 2023

FDA offers a status check on its diversity in research provisions, one year post-FDORA At a workshop on FDA’s implementation of new statutory requirements for diversity in clinical research, agency and industry representatives gave a status update on implementation. FDORA also directed the FDA to convene a meeting. countries.

FDA 40

FDA Research Clinical Trials Trials 40

The Premier Consulting Blog

NOVEMBER 12, 2023

This feedback prompted the FDA to release a second paper in 2021 titled “ Artificial Intelligence/Machine Learning (AI.ML)-Based Software as a Medical Device (SaMD) Action Plan ,” which outlined the agency’s five-pillar approach to regulating AI/ML.

FDA 52

FDA Drug Development Regulations FDA Approval 52

FDA Law Blog: Biosimilars

AUGUST 23, 2023

By the end of Q2 FY 2023, FDA will convene the first of a series of 5 public meetings or workshops with key stakeholders including patients, biopharmaceutical companies, DHT companies, and academia to gather input into issues related to the use of DHTs in regulatory decision-making. By Adrienne R.

Production 52

Production Clinical Trials FDA Drugs 52

Drug Channels

OCTOBER 12, 2020

Join Informa Connect-CBI’s 6th Edition Drug Pricing Transparency Congress to discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Offer not valid on workshop only or academic/non-profit registrations. Informa Connect-CBI will see you there!

Drugs 40

Drugs Compliance International Regulations 40

Agency IQ

MAY 10, 2024

The new guidance maintains the agency’s existing definitions of remanufacturing and servicing, but adds a new section that provide a high level overview of the medical device regulations – primarily for those “less familiar.” Also this year, the FDA finalized its new rule on overhauling the medical device quality system regulations.

FDA 40

FDA Regulations Compliance Production 40

Drug Channels

SEPTEMBER 29, 2020

As managing copay programs continues to be significantly more complex, it is imperative to stay on top of current trends, emerging regulations and future legislation. Offer not valid on workshop-only or non-profit registrations. It’s time to talk. Drug Channels, or any of its employees.

Pharmacy 40

Pharmacy Pharmaceuticals Compliance Regulations 40

Agency IQ

JANUARY 19, 2024

The work could represent early steps toward modernizing one part of FDA’s regulation of this complicated product class. The agency also hosts regular workshops related to generic drug regulatory science topics, such as a May 2023 workshop to discuss technical issues, policy gaps and advice for developers of drug-device combination products.

FDA 40

FDA Research Production Regulations 40

Advarra

NOVEMBER 29, 2022

However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines. Taken together, these initiatives offer more frequent interactions between sponsors and regulators to communicate and discuss technological advances.

Therapies 52

Therapies Clinical Trials FDA Trials 52

Perficient: Drug Development

JUNE 13, 2024

Offering workshops, certifications, and continuous learning opportunities can keep professionals updated on best practices and emerging trends. Government regulations and incentives can encourage businesses to invest in accessible design.

Engineering 52

Engineering Compliance Government Regulations 52

Agency IQ

JUNE 26, 2023

Regulation (EC) No 141/2000 (the Orphan Regulation) provides the legal framework for orphan drug designations and incentives.The Orphan Regulation entered into force in January, 2000, outlining requirements for orphan designation and incentives, and establishing the EMA Committee for Orphan Medicinal Products (COMP). regulators.

FDA 40

FDA Disease Regulations Production 40

Agency IQ

OCTOBER 27, 2023

MHRA, FDA and Health Canada offer “guiding principles” for predetermined change control plans Regulators from the U.S., The regulators suggest that PCCPs need to be transparent, risk-based, bounded and operate throughout the product life cycle. Internationally, regulators are building a framework AI/ML in regulated products.

FDA 40

FDA Regulations International Production 40

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. This class-wide issue been an ongoing point of discussion both in the U.S. and in Europe.

FDA 40

FDA Trials Therapies Regulations 40

Agency IQ

NOVEMBER 20, 2023

Summary of Product Characteristics and Package Leaflet), recommending that sponsors and regulators “explore the use of electronic media” to provide product information “in the future”. If the ePI is approved by the regulator, then it will be made publicly available in the ePI database.

Production 40

Production Packaging Hospitals Regulations 40

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The workshop is also discussed in Cell & Gene here and here.

Therapies 59

Therapies Engineering Production FDA 59

Agency IQ

JUNE 2, 2023

Proposal for a regulation Initiative entry Chemicals – making best use of EU agencies to streamline scientific assessments Adoption is planned for second quarter of 2023 The European Green Deal aims to move towards a ‘one substance, one assessment’ process for chemical safety assessments.

Regulations 40

Regulations Production International Marketing 40

Agency IQ

FEBRUARY 23, 2024

Background: PFAS regulation in California PFAS have been the subject of significant regulations in California, beginning in the 2010s [for an in-depth review of PFAS regulation in California, see the AgencyIQ analysis here ]. In 2019, the state began to significantly ramp up its PFAS regulation and research.

Packaging 40

Packaging Regulations Production Compliance 40

Agency IQ

MARCH 15, 2024

regulators on the methods used to evaluate high-risk medical devices, with a particular focus on clinical evidence. The 22 consortium members comprise Member State regulators (e.g., The 22 consortium members comprise Member State regulators (e.g., Regulators are interested in the use of these tools.

Research 40

Research Regulations Clinical Trials Trials 40

Agency IQ

APRIL 19, 2024

The conduct and infrastructure of clinical trials is heavily regulated, and updates to the methods, approaches, designs, or technologies employed can have regulatory implications. In particular, regulations in both the U.S. In particular, regulations in both the U.S.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Agency IQ

AUGUST 11, 2023

Since this discovery, it’s been unclear how regulators or sponsors might assess or address these potential risks. Clearly, the scope of the issue has grown substantially compared to what was covered in the initial guidances and AI recommendations provided by regulators in the last several years. “To ensure the safety of the U.S.

FDA 40

FDA Science Production Regulations 40

Agency IQ

JULY 13, 2023

December 31, 2022 [link] PDUFA 50 issue a new MAPP on approaches to address CMC challenges for CDER-regulated products (drugs, biologics) with accelerated clinical development timelines (e.g.,

Science 40

Science FDA Biosimilars Production 40

Agency IQ

AUGUST 9, 2024

EMA’s psychedelic workshop leaves stakeholders with as many questions as answers Earlier this year, the EMA hosted a multi-stakeholder workshop to discuss regulatory issues surrounding drug development of psychedelic products. EMA has now published a report on the workshop; read on for AgencyIQ’s analysis. Although the E.U.

Clinical Trials 40

Clinical Trials Regulations Trials FDA 40

Agency IQ

MARCH 1, 2024

What we expect European regulators to do in March 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Biosimilars Clinical Trials Production 40